Subscribe: Market Wire - Pharmaceuticals and Biotech: Trials
http://img.marketwire.com/rss/mwPBTR.rss
Added By: Feedage Forager Feedage Grade B rated
Language: English
Tags:
announced  announces  clinical  company  development  jan  january  marketwired jan  marketwired january  marketwired  new  today 
Rate this Feed
Rate this feedRate this feedRate this feedRate this feedRate this feed
Rate this feed 1 starRate this feed 2 starRate this feed 3 starRate this feed 4 starRate this feed 5 star

Comments (0)

Feed Details and Statistics Feed Statistics
Preview: Market Wire - Pharmaceuticals and Biotech: Trials

Marketwired - Trials



Marketwired - Trials



Last Build Date: Tue, 24 Jan 2017 09:58:47 EST

Copyright: Copyright: (C) Marketwired
 



Pacgen Announces New Markets for P113 Products

Tue, 24 Jan 2017 09:30:00 EST

VANCOUVER, BC--(Marketwired - January 24, 2017) - Pacgen Life Science Corporation ("Pacgen" or the "Company") (TSX VENTURE: PBS) announced today that its partner, General Biologicals Corporation ("GBC") (Taiwan OTC: 4117.TWO), has added new markets for P113 products licensed from Pacgen. Subject to regulatory approval, P113 mouth rinse and mouth sprays will be made available in Southern China in addition to their existing markets in Taiwan.




PharmaCyte Going Head to Head with Eli Lilly's Pancreatic Cancer Drug in New Clinical Trial

Tue, 24 Jan 2017 09:10:00 EST

NEW YORK, NY--(Marketwired - January 24, 2017) - Ten years ago the National Cancer Institute (NCI) recognized the rise in pancreatic cancer deaths and called for the development of better treatments. The NCI encouraged developers to design more clinical trials that don't use the chemotherapy drug gemcitabine as part of their treatment. PharmaCyte Biotech (OTCQB: PMCB) is on the doorstep of doing just that -- developing a treatment that doesn't use gemcitabine, and instead the company has designed a clinical trial that will actually go head to head with gemcitabine.




Propanc Provides Progress Update on Additional Patent Applications

Tue, 24 Jan 2017 08:30:00 EST

MELBOURNE, AUSTRALIA--(Marketwired - January 24, 2017) - Propanc Health Group Corporation (OTCQB: PPCH) ("Propanc" or "the Company"), an emerging healthcare company focusing on development of new and proprietary treatments for cancer patients suffering from solid tumors such as pancreatic, ovarian and colorectal cancers, today announced an update on the progress of additional pending patent applications, since the recent allowance of the Company's first key patent application in the US this year.




SHYFT Analytics Appoints Joseph Tyers to Chief Revenue Officer

Tue, 24 Jan 2017 08:00:00 EST

Life Sciences Software Executive to Lead Commercial Team




Propel Medical Review with Guided Analytics, New Webinar Hosted by Xtalks

Tue, 24 Jan 2017 07:30:00 EST

TORONTO, ON--(Marketwired - January 24, 2017) - During a live webcast on Tuesday, February 7, 2017 at 11am EST (4pm GMT/UK), industry expert Masha Hoffey, Director of Clinical Analytics for the Informatics team, at PerkinElmer will discuss how medical monitors can leverage guided visual analytics to find and act on the right issues quickly without sifting through mounds of clinical data, allowing monitoring teams to perform in-stream review of study data and make smarter decisions faster.




Nephros Provides Corporate Update and Fourth Quarter 2016 Revenue Guidance

Tue, 24 Jan 2017 07:30:00 EST

Projects Positive Cash Flow by Mid 2017




Quidel Announces Modification of Revenue Reporting Categories

Mon, 23 Jan 2017 19:00:00 EST

SAN DIEGO, CA--(Marketwired - January 23, 2017) - Quidel Corporation (NASDAQ: QDEL), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today that it will modify its presentation of the components of its major revenue categories.




Corcept Therapeutics to Announce Preliminary 2016 Financial Results, Provide 2017 Revenue Guidance and Corporate Update, and Host Conference Call

Mon, 23 Jan 2017 16:05:00 EST

MENLO PARK, CA--(Marketwired - Jan 23, 2017) - Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will report preliminary fourth quarter and full year 2016 financial results and provide 2017 revenue guidance and a corporate update on January 30, 2017. The company will also host a conference call that day at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time).




mCig Announces 5 Million Reduction in Shares Outstanding

Mon, 23 Jan 2017 16:00:00 EST

HENDERSON, NV--(Marketwired - Jan 23, 2017) -  mCig Inc. (OTCQB: MCIG), a diversified company servicing the legal cannabis, hemp, and CBD markets, announced today that it has begun the process of cancelling 5 million shares of its common stock. 




C.R. Bard, Medikit Lead Japan Vascular Access Market Fueled by Switch from Central Venous to Peripherally Inserted Central Catheters

Mon, 23 Jan 2017 13:24:55 EST

The increasing prevalence of diseases and conditions that require long-term vascular access is fueling the increased use of vascular access devices and is expected to be a driving factor in the Japanese market




Advantis Corp. Developing Rosin Press for Home Use

Mon, 23 Jan 2017 09:26:00 EST

NEWPORT BEACH, CA--(Marketwired - Jan 23, 2017) - ADVANTIS CORPORATION (OTC PINK: ADVT) is currently developing a rosin press designed for home use. The company is adding to its current line up of rosin presses, and is in negotiations to have a well known personality in the cannabis industry represent the Advantis products.




PHZIO Telehealth Marketing Campaign

Mon, 23 Jan 2017 09:00:00 EST

CULVER CITY, CA--(Marketwired - Jan 23, 2017) - eWellness Healthcare Corporation, (OTCQB: EWLL) is the first telehealth company for physical therapy to offer insurance reimbursable remotely monitored physical therapy (PT) treatments. The Company has begun direct marketing telephone and email campaigns to multi-clinical PT practices throughout the state of California. The Company has also launched procative marketing campaigns to nationwide PT's on LinkedIn and Facebook. The Company also successfully held its initial webinar last week. Please see the following link to view this webinar: https://wnarchives.s3.amazonaws.com/45426582/62c11c14-baa2-4ad7-b8cd-521b38fd3542/archive.mp4. We also recently updated our PHZIO website that is available at: https://www.phzio.com




GeoVax Announces Initiation of HIV Human Clinical Trial

Mon, 23 Jan 2017 09:00:00 EST

ATLANTA, GA--(Marketwired - Jan 23, 2017) - GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company developing human vaccines, announced today the initiation of the next human clinical trial of GeoVax's preventive HIV vaccine, GOVX-B11. The Phase 1 trial (designated HVTN 114) is being conducted by the HIV Vaccine Trials Network (HVTN) and is funded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH).




Ritter Pharmaceuticals Announces Collaboration with University of Nebraska to Explore Development of Microbiome Therapeutics in Metabolic Syndrome

Mon, 23 Jan 2017 09:00:00 EST

LOS ANGELES, CA--(Marketwired - Jan 23, 2017) - Ritter Pharmaceuticals, Inc. (NASDAQ: RTTR) ("Ritter Pharmaceuticals" or the "Company"), a pharmaceutical company developing novel therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases, today announced that it is collaborating with the newly-established Food for Health Center at the University of Nebraska ("NU") to study the role of the microbiome and RP-G28 in metabolic syndrome.




GB Sciences Resets: Exclusive Executive Interview with CFN Media

Mon, 23 Jan 2017 09:00:00 EST

SEATTLE, WA--(Marketwired - Jan 23, 2017) - CFN Media Group ("CannabisFN"), the leading creative agency and media network dedicated to legal cannabis, announces publication of an article and interview discussing recent developments and the path forward for GB Sciences Inc. (OTCQB: GBLX).




Zenosense, Inc.: New Patent Application for Additional MIDS Detection Method

Mon, 23 Jan 2017 08:30:00 EST

VALENCIA, SPAIN--(Marketwired - Jan 23, 2017) -  Zenosense, Inc. (OTCQB: ZENO) ("Zenosense", the "Company"), a healthcare technology company primarily focused on the development and commercialization of MIDS CardiacT, a Point of Care ("POC") handheld device for the early detection of certain cardiac event biomarkers to significantly accelerate the triage, diagnosis, treatment and disposition of patients reporting chest pain and with suspected acute myocardial infarction (heart attack), is pleased to announce that MIDS Medical Limited ("MML"), our 40% owned joint venture based at Sci-Tech, Daresbury, UK has submitted a UK Intellectual Property Office patent application for an additional MIDS detection method.




Helix BioPharma Corp. Announces CAR-T Poster Presentation at AACR Annual Meeting 2017 in Washington, DC

Mon, 23 Jan 2017 07:45:00 EST

CAR-T cell harboring a camelid single domain antibody as a targeting agent to kill tumours expressing VEGFR2




Medigus Receives First Purchase Order for MUSE in Italy

Mon, 23 Jan 2017 07:00:00 EST

OMER, ISRAEL--(Marketwired - Jan 23, 2017) - Medigus Ltd. (NASDAQ: MDGS) (TASE: MDGS), a medical device company developing minimally invasive endosurgical tools and a leader in direct visualization technology, today announced that it received the first purchase order (PO) for the MUSET system in Italy from INNOVAMEDICA S.p.A, a privately-owned distributor of minimally invasive medical devices, in accordance with their existing distribution agreement.




Omni Health, Inc. Reports $1.0M Net Income and a $1.6M Consolidated Proforma Income for 1st Quarter of Fiscal Year 2017

Mon, 23 Jan 2017 07:00:00 EST

MIAMI, FL--(Marketwired - Jan 23, 2017) - Omni Health, Inc. (OTC PINK: OMHE), a pharmaceutical company, filed today its first quarter results for fiscal year 2017, ending July 31, 2016. OMHE recorded a $1.08M net income, which incorporated Malecon Pharmacy, Inc., a wholly owned subsidiary of OMHE as of June 22, 2016. In addition to the results, and in accordance with ASC 805-10-50, the Company provided the results of net income of the combined results of the Company's consolidated operations with the acquisition as if the acquisition had been completed as of the beginning of the reporting period. As such, the proforma results was $1.6M Net Income. The Company recognized a one-time sale of discontinue operations of VitaCig to mCig, Inc. (OTC: MCIG), in the amount of $1.1M leaving a $500K adjusted proforma net income for the consolidated quarter.




Prima BioMed to Present at 2nd Annual Cancer Immunotherapy Conference

Sun, 22 Jan 2017 19:00:07 EST

SYDNEY, AUSTRALIA--(Marketwired - Jan 22, 2017) - Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD) ("Prima" or the "Company") announces that the submission titled "TACTI-mel, Two ACTive Immunotherapies in Melanoma: Combination of IMP321 (LAG-3Ig) with an Anti-PD-1 Antagonist in a Phase I Trial" has been accepted for a presentation at the 2nd Annual Cancer Immunotherapy Conference, part of 24th International Molecular Medicine Tri-Conference, in San Francisco, California, between February 20 - 22, 2017.




New Xtalks Webinar on Clinical Evaluation Reports (CERs): Global Benefits and The Impact of MEDDEV Updates to Manufacturers

Fri, 20 Jan 2017 07:30:00 EST

During a live broadcast, the speaker will examine the requirements listed in MEDDEV 2.7/1 revision. 4, discuss notable changes from MEDDEV 2.7/1 revision 3, while focusing on the global benefits of the Clinical Evaluation Report for your product's path to market.




Prima BioMed Commences Randomised Phase IIb Clinical Trial for IMP321 in Breast Cancer

Thu, 19 Jan 2017 18:07:57 EST

SYDNEY, AUSTRALIA--(Marketwired - Jan 19, 2017) - Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD) ("Prima" or the "Company") today announced the first patient has been dosed as part of the enlarged randomised phase of its AIPAC Phase IIb clinical trial for IMP321 in metastatic breast cancer.




IntelGenx Grants Stock Options

Thu, 19 Jan 2017 16:15:00 EST

SAINT-LAURENT, CANADA--(Marketwired - Jan. 19, 2017) - IntelGenx Technologies Corp. ("IntelGenx", or the "Company") (TSX VENTURE:IGX)(OTCQX:IGXT) announced today that the Company's board of directors granted options to acquire a total of 300,000 common shares under the 2016 Stock Option Plan.




Newly Created Standards Coordinating Body Seeks to Advance Development and Establishment of Regenerative Medicine Standards

Thu, 19 Jan 2017 15:23:19 EST

Builds upon call for standards development in 21st Century Cures Act




The Alliance for Regenerative Medicine Launches Standards Coordinating Body to Advance Development and Establishment of Industry-Wide Standards

Thu, 19 Jan 2017 12:22:41 EST

Builds upon call for standards development in 21st Century Cures Act




UPDATE - Greenhouse Solutions, Inc. Issues Company Update

Thu, 19 Jan 2017 12:05:47 EST

GREENWOOD VILLAGE, CO--(Marketwired - Jan 19, 2017) -  Greenhouse Solutions, Inc. (OTC PINK: GRSU) ("GH Solutions"), a company focused on creating and offering nutritional products with hemp supplements, is pleased to provide a Distributor Update and news on a distribution improvement that is being implemeted to the KOIOS Raspberry Wonder with Hemp beverage.




Amedica Announces Pricing of Public Offering to Raise $4.5 Million

Thu, 19 Jan 2017 09:46:33 EST

SALT LAKE CITY, UT--(Marketwired - Jan 19, 2017) -  Amedica Corporation (NASDAQ: AMDA), a company that develops and commercializes silicon nitride ceramics, today announced the pricing of an underwritten public offering of common stock and warrants with a public offering price of $0.51 for one share of common stock and 0.45 warrants. Each whole warrant is exercisable for one share of common stock. The Company expects to receive gross proceeds of approximately $4.5 million, before deducting underwriting discounts and commissions and other estimated offering expenses. The Company has also granted a 45-day option to the underwriters to purchase up to an additional 15% of the shares of common stock plus up to 15% of the warrants; provided that in no event may the aggregate market value of securities sold in the offering, including from the over-allotment option, exceed the limitations set forth in Rule I.B.6 of Form S-3 solely to cover over-allotments, if any.




Vaxil Bio Expands Into Infectious Diseases With First US Patent for MTbuVax(TM)

Thu, 19 Jan 2017 09:30:00 EST

Receives USPTO Notice of Allowance for MTbuVax(TM) Family of Signal Peptide Vaccines and their use in Treating Major Infectious Diseases




Abattis Explores Diversifying with a Strategic Acquisition -- CFN Media

Thu, 19 Jan 2017 09:15:00 EST

SEATTLE, WA--(Marketwired - Jan 19, 2017) -  CFN Media Group, the leading creative agency and digital media network dedicated to legal cannabis, announces the publication of an article discussing Abattis Bioceuticals Corp. (OTC PINK: ATTBF) (CNSX: ATT), a specialty agricultural technology firm focused on the legal cannabis industry. The company recently commissioned an independent valuation on Green Nature Health Care Products Inc. in advance of a potential strategic acquisition. The move would follow the company's international licensing and co-branding agreement signed in November of last year and Green Nature's strong financial performance since then.




AssistRx Acquires Caret(TM), Providing Users with Cutting Edge Technology to Boost Patient Care Management, Adherence, and Compliance

Thu, 19 Jan 2017 09:01:00 EST

ORLANDO, FL--(Marketwired - Jan 19, 2017) -  AssistRx (ARx), the leading enterprise technology platform focused on simplifying the patient journey for specialty and highly-managed medications, today announces its acquisition of Caret, and Caret's Care Management Platform. Caret provides healthcare providers, specialty pharmacies, patients, and payers a best-in-class communication platform powered by actionable data such as point-of-service decision making, care management programs and near real-time updates on patients. ARx plans to integrate these features into the AssistRx Platform, to enhance the patient journey, drive quality-based healthcare, and improve outcomes.




InMed Pharma Appoints Eli Lilly Finance Executive to Board of Directors -- CFN Media

Thu, 19 Jan 2017 09:00:00 EST

SEATTLE, WA--(Marketwired - Jan 19, 2017) - CFN Media Group, the leading creative agency and digital media network dedicated to legal cannabis, announces the publication of an article discussing InMed Pharmaceuticals Inc.'s (OTCQB: IMLFF) (CNSX: IN) recent appointment of Martin Bott to its Board of Directors, the company's existing team, and what it means as InMed progresses towards its first clinical trial in INM-750 for the treatment of Epidermolysis Bullosa as well as the rest of its clinical pipeline.




AXIM Biotech Begins CanChew Plus Clinical Trials -- SECFilings.com

Thu, 19 Jan 2017 09:00:00 EST

REDONDO BEACH, CA--(Marketwired - Jan 19, 2017) - SECFilings.com, a leading financial news and information portal offering free real time public company filing alerts, announces the publication of an article covering AXIM® Biotechnologies Inc.'s (OTCQB: AXIM) recently announced clinical trials evaluating its CanChew Plus® cannabidiol (CBD) gum for the treatment of irritable bowel syndrome (IBS).




70% of Global Drug Safety Teams Outsource Case Management Activities

Thu, 19 Jan 2017 07:44:00 EST

RESEARCH TRIANGLE PARK, NC--(Marketwired - January 19, 2017) - Data published by pharmaceutical competitive intelligence firm Cutting Edge Information found that literature services are the most commonly outsourced item among 70% of surveyed pharmacovigilance teams.




Vertical Integration of CRISPR/Cas9 Genome Engineering in Drug Discovery, New Webinar Hosted by Xtalks

Thu, 19 Jan 2017 07:30:00 EST

TORONTO, ON--(Marketwired - January 19, 2017) - Industry expert Dr. Anne-Marie Zuurmond, Associate Director of Genome Engineering, Discovery, Charles River Laboratories will discuss several CRISPR/Cas9 case studies during this webinar covering different aspects of the drug discovery process with an emphasis on the generation of in vitro models for high-throughput screening and the creation of new mouse models of disease.




Moleculin Announces Expanded Scientific Advisory Board

Thu, 19 Jan 2017 07:00:00 EST

HOUSTON, TX--(Marketwired - January 19, 2017) - Moleculin Biotech, Inc., (NASDAQ: MBRX) ("Moleculin" or the "Company"), a preclinical pharmaceutical company focused on the development of anti-cancer drug candidates, many of which are based on license agreements with The University of Texas System on behalf of the M.D. Anderson Cancer Center, today announced that Drs. Sandra Silberman and Paul Waymack have joined the Company's Scientific Advisory Board (SAB). The Company's current SAB also includes Dr. Waldemar Priebe (Chair) and Dr. Madeleine Duvic.




Optymyze Takes the Gold in Brandon Hall Group's 2016 Excellence in Technology Awards

Thu, 19 Jan 2017 07:00:00 EST

Optymyze Sales Operations is Recognized for Best Advance in Sales Enablement and Performance Tools




Proto Script Pharmaceutical Corp. Building New Partnerships with Independent Practice Associations (IPA)

Thu, 19 Jan 2017 06:00:00 EST

RANCHO CUCAMONGA, CA--(Marketwired - Jan 19, 2017) - Proto Script Pharmaceutical Corp. dba PSP Homecare ("PSP" or the "Company") (OTC PINK: PSCR), a durable medical equipment provider, today provided this update regarding its current business and future expansion plans with Independent Practice Associations.




Targazyme Inc. Receives Additional U.S Patent Award Designed to Improve Cell Therapy Clinical Efficacy Outcomes

Wed, 18 Jan 2017 16:16:23 EST

CARLSBAD, CA--(Marketwired - January 18, 2017) - Targazyme Inc., a clinical stage biopharmaceutical company developing novel enzyme technologies and products to improve clinical efficacy, safety and cost of care outcomes for patients undergoing cancer immunotherapy, stem cell transplantation and regenerative medicine, announced today that the United States Patent & Trademark Office has awarded Targazyme, Patent 9,511,095 entitled "Cells Treated by In-Vitro Fucosylation and Methods of Production and Use Thereof".




Amedica Announces Proposed Public Offering of Common Stock and Warrants

Wed, 18 Jan 2017 16:01:00 EST

SALT LAKE CITY, UT--(Marketwired - Jan 18, 2017) - Amedica Corporation (NASDAQ: AMDA), a company that develops and commercializes silicon nitride ceramics, today announced that it intends to offer and sell common stock and warrants, subject to market and other conditions, in an underwritten public offering. The common stock and warrants are being offered under the Company's effective shelf registration statement previously filed with the Securities and Exchange Commission (SEC). Net proceeds from the offering will be used by Amedica to (1) remain in compliance with the financial covenants in its outstanding Loan and Security Agreement; (2) support working capital needs and other general corporate purposes; (3) fund research and development and commercialization activities of Amedica's product candidates, including the funding of clinical trials Amedica plans to conduct for its product candidates; and (4) continue to build sales, marketing and distribution capabilities for Amedica's silicon nitride technology platform and other products, including the costs of inventory and instruments.




PHZIO Telehealth Webinar Link

Wed, 18 Jan 2017 13:30:36 EST

CULVER CITY, CA--(Marketwired - Jan 18, 2017) - eWellness Healthcare Corporation, (OTCQB: EWLL) is the first telehealth company for physical therapy to offer insurance reimbursable remotely monitored physical therapy (PT) treatments. The Company successfully held its initial webinar this morning. Please see the following link to view this webinar: https://wnarchives.s3.amazonaws.com/45426582/62c11c14-baa2-4ad7-b8cd-521b38fd3542/archive.mp4. More information about our telehealth solution is available at our PHZIO.COM website: https://www.phzio.com




Brown Technical Media Corp. Announces Uplist to the QB Tier of the OTC Markets

Wed, 18 Jan 2017 10:30:00 EST

HOUSTON, TX--(Marketwired - Jan 18, 2017) - Brown Technical Media Corp., a division of Panther Biotechnology Inc. (OTCQB: PBYA), an e-commerce company building the first full service training and career advancement brand for the skilled trades, is pleased to announce today that it has been accepted for up listing to the OTCQB effective immediately.




Premier Biomedical Pain Management Solutions Announces Product Distribution Agreement of Their Superior Pain Relief Products

Wed, 18 Jan 2017 10:15:00 EST

EL PASO, TX--(Marketwired - Jan 18, 2017) - Premier Biomedical, Inc. (OTCQB: BIEI) announced today their newly created joint venture company, Premier Biomedical Pain Management Solutions, LLC (PBPMS) has signed a distribution agreement contract with the Pain Relief & Wellness Strategy Center in Grove City, Pennsylvania to sell and distribute its pain relief products. Initially, the contract will cover pain relief patches and roll-ons, but will expand as new products are introduced.




EAG Laboratories Adds New Capabilities in Dermal Absorption Testing

Wed, 18 Jan 2017 09:00:00 EST

HERCULES, CA--(Marketwired - Jan 18, 2017) - EAG Laboratories, a global scientific services company that provides testing, analytical and characterization services to technology- and life-science-related industries, announced the addition of dermal absorption studies to its suite of GLP-compliant testing services. The company now offers testing outlined in OECD 427 (in vivo studies in rodent models) and OECD 428 (in vitro studies using human and animal skin), which are often performed in parallel to predict dermal absorption in humans (sometimes called "the triple pack" or "parallelogram" approach).




Predictive Technology Group, Inc. (PRED) Reaches Key Clinical Milestone in Development of Genetic Tests for Infertility and Endometriosis

Wed, 18 Jan 2017 09:00:00 EST

Development of ARTGuide(R) Test Will Rapidly Accelerate Short-Term Company Growth




Biomerica Announces Second Quarter Financial Results; Sales up Over 22% for the Quarter

Wed, 18 Jan 2017 08:19:00 EST

IRVINE, CA--(Marketwired - January 18, 2017) - Biomerica, Inc. (NASDAQ: BMRA) today reported net sales of $1,432,206 for the three months ended November 30, 2016, compared to $1,165,080 for the same period in the previous year, an increase of 22.9%. Net sales were $2,842,317 for the first six months of fiscal 2017 compared to $2,452,073 for the first six months in fiscal 2016, an increase of 15.9%.




Pharma Compliance Teams Approving Physician Compensation Cap Exceptions

Wed, 18 Jan 2017 08:17:00 EST

RESEARCH TRIANGLE PARK, NC--(Marketwired - January 18, 2017) - Although more pharmaceutical companies have instituted compensation limits as a response to scrutiny over their payments to physicians, there are still exceptions to those rules.




Vinergy Resources/MJ Biopharma Appoint Scientific Advisory Board Chair to Pursue Clinical Testing of Cannabinoids for Therapeutics

Wed, 18 Jan 2017 08:00:00 EST

VANCOUVER, BRITISH COLUMBIA--(Marketwired - Jan. 18, 2017) - Vinergy Resources Ltd. ("Vinergy" or the "Company") (CSE:VIN)(CSE:VIN.CN) in conjunction with its proposed acquisition of MJ Biopharma (announced December 14, 2016) is pleased to announce that it has appointed Dr. William Panenka, MD as Chair of the Company's Scientific Advisory Board (SAB). Bringing on the right human capital through strategic hires is an important part of the Company's strategy to develop, test and identify specific cannabinoid isolates for targeted therapeutic purposes.




Upcoming Webinar on Development by Design: Hovione's Approach to Spray Drying Process Development

Wed, 18 Jan 2017 07:30:00 EST

TORONTO, ON--(Marketwired - January 18, 2017) - On Tuesday, January 31, 2017, Xtalks will host a complimentary webinar featuring Márcio Temtem, Associate Director of Particle Design and Formulation Development at Hovione and João Vicente, Team Leader of Particle Engineering and Solubility Enhancement at Hovione, as the keynote speakers.




MediXall Appoints Dr. Pedro A. Sanchez, D.O., to be its First Medical Director

Wed, 18 Jan 2017 07:30:00 EST

FT. LAUDERDALE, FL--(Marketwired - Jan 18, 2017) - MediXall Group, Inc. (OTCQB: MDXL) is pleased to announce the appointment of its first Medical Director, Dr. Pedro A. Sanchez, D.O. Dr. Sanchez is a graduate of Southeastern College of Osteopathic Medicine in Ft. Lauderdale, Florida, and served his residency at Wellington Regional Medical Center in Wellington, Florida. Dr. Sanchez is Board Certified by the American Osteopathic Board of Family Physicians, and has been a successful family practice physician for over 25 years.




Omni Health, Inc. names Andrey Soloviev as New CEO

Wed, 18 Jan 2017 07:25:04 EST

MIAMI, FL--(Marketwired - Jan 18, 2017) -  Omni Health, Inc., (OTC PINK: OMHE), a pharmaceutical company, announced today the Board of Directors has selected Andrey Soloviev as its new Chief Executive Officer. Mr. Soloviev will take over, effective immediately, for interim CEO, Michael Hawkins, who shall remain the company's interim CFO. 




Prima BioMed to Maintain NASDAQ Listing

Wed, 18 Jan 2017 02:02:58 EST

SYDNEY, AUSTRALIA--(Marketwired - Jan 18, 2017) - Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD) the "Company" has received notification from the Listing Qualifications Department of the NASDAQ Stock Market indicating that the Company's American Depositary Shares have maintained a closing bid price of US$1.00 per share or greater for 10 consecutive business days from 28 December 2016 to 11 January 2017. Accordingly, the Company has regained compliance with NASDAQ Listing Rule 5450(a)(1) (the "Minimum Bid Price Rule") and the Company's American Depositary Shares will remain listed on the NASDAQ Global Market.




Medifirst Solutions to Present Its Time Machine Laser in Morocco and Dubai

Tue, 17 Jan 2017 11:00:00 EST

FREEHOLD, NJ--(Marketwired - Jan 17, 2017) - MEDIFIRST SOLUTIONS, INC. (OTCQB: MFST) (the "Company" or "Medifirst") would like to update shareholders regarding its previous announcement about international sales for its FDA cleared Infrared Time Machine TTML-8102000 Laser Thermal Therapeutic Device.




Health Advance Announces the Closing of the Acquisition of Hantian Labs

Tue, 17 Jan 2017 10:45:10 EST

LAS VEGAS, NV--(Marketwired - Jan 17, 2017) -  Health Advance Inc. (the "Company") (OTC PINK: HADV) is pleased to announce that the Company has closed the Share Exchange Agreement ("Agreement") to acquire Hantian Labs Limited, a private UK corporation (Hereinafter referred to as "Hantian"). As a result of the acquisition, Health Advance will also control 99% of JT Hantian LLC representing the revenue arm of Hantian. Pursuant to the Agreement, the Company has issued 18,000,000 common shares of the Company to the shareholders of Hantian Labs representing the purchase price of Hantian. Accordingly, the Company's issued and outstanding number of common shares increased from 26,520,000 shares to 44,520,000 shares. In addition, Company has waived Hantian's undertaking to raise a minimum financing of $250,000 for marketing of Hantian's product line prior to closing.




Tufts Clinical and Translational Science Institute and Baim Institute for Clinical Research Announce Partnership

Tue, 17 Jan 2017 10:10:00 EST

Students, Faculty, Researchers, and Patients to Benefit from New Collaboration




Pegasystems Advances Pega Product Composer System for Health Insurers to Offer More Personalized Plans and Optimal Customer Experience

Tue, 17 Jan 2017 10:00:00 EST

With Pega PCS, improved data access allows insurers to bring new products to market faster while enabling better collaboration and transparency